Trial intelligence / Profile preview

Phase II three-cohort study of INC280 in EGFR wild-type previously treated advanced or metastatic non-small cell lung cancer in Chinese adults

CTR20171317Phase 2Suspended

Sponsor

Novartis

Start

Nov 2017

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1